Polymeric Micelles in Cancer Immunotherapy

Purpose: Cancer immunotherapy can produce durable clinical responses, but systemic delivery of immunostimulatory agents is limited by short half-lives, off-target toxicities (e.g., cytokine release syndrome), low response rates (10–30%), and poor efficacy in solid tumors. Polymeric micelles offer a biocompatible, modifiable, core–shell delivery platform that can improve bioavailability, enable tumor accumulation via the EPR effect, and reduce systemic adverse effects. This review summarizes recent advances in polymeric micelles for cancer immunotherapy.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that polymeric micelles — self-assembled from amphiphilic polymers with hydrophilic and hydrophobic domains — can improve the safety and efficacy of cancer immunotherapies by encapsulating and delivering cytokines, vaccines, checkpoint inhibitors, molecular adjuvants, and TME-modulating agents, and by enabling multifunctional, stimuli-responsive, and targeted delivery.

Aims: Summarize cancer immunosuppression mechanisms and strategies for cancer immunotherapy. - Review polymeric micelle systems for delivery of cytokines (IL-2, IL-12, M-CSF). - Review polymeric micellar cancer vaccines, including DC vaccines, nucleic acid vaccines, TCLs, and neoantigens. - Review polymeric micelles for immune checkpoint inhibitors (NLG919, indoximod, 1-MT, CTLA-4 siRNA, anti-PD-1). - Review polymeric micelles for molecular adjuvants (R837, R848, CpG, MPLA, poly(I:C)). - Describe TME modulation and engineered T cell applications. - Discuss clinical and preclinical impact and future perspectives.

Delivery system: Carrier type: Polymeric micelles, self-assembled from amphiphilic block or graft copolymers with core–shell architecture. - Polymers used: PEG-pGlu, PMet-P(cdmPEG2K), HA-PMet, PEG-b-PGA, PEOz-PLA, carboxylated Pluronic F127, PEG-PE, PSA, curcumin-PEG, PLGA-PEG, PEG-b-PAGE-b-PLGA, P[Asp(DET)]/PEG-b-P[Asp(DET)], PEG-PLL-PLLeu, MPEG-PCL, PEG2k-Fmoc-NLG, PSSN10, POEG-b-PVBDND, PEG2k-Fmoc-1-MT, PEG-P(MLT), PEG-PLA, azide-PEG-PAsp(Dip/Bz), AC-CS-PpIX (ACP), PBA-PEG-PCL, POx (BuOx/MeOx), mPEG-bPEI-PEBP. - Payloads: Cytokines (IL-2, IL-12 plasmid, M-CSF), antigens (OVA, Trp2, SART3), adjuvants (CpG ODN, R837, R848, MPLA, poly(I:C), CL264), checkpoint inhibitors (NLG919, indoximod, 1-methyl-1-tryptophan, CTLA-4 siRNA, anti-PD-1 peptide), chemotherapeutics (DOX, PTX, sunitinib), and CAR-encoding plasmids. - Targeting/functional features: Lymph node targeting, DC targeting (fucose, mannose, N-acetyl glucosamine, anti-DEC205, anti-CD11c), TAM targeting via CD206, pH-responsive de-shielding, redox-responsive release, MMP/pH dual-sensitive release, and hypoxia reversal.

Approach: Review of preclinical and clinical literature. In vitro models include DCs, macrophages, Jurkat cells, Panc02, 4T1, B16, EG7, CT26, TC-1, and CD19-K562 cells. In vivo models include mice bearing lymphoma, breast cancer, melanoma, colon cancer, lung cancer, and metastatic NSCLC. No new primary experiments, group sizes, or doses are reported.

Key methods: Cytokine production and immune cell activation assays (IFN-γ, IL-2, TNF-α). - DC maturation markers (CD40, CD80, CD86, MHC). - T cell proliferation, CTL activity, and Treg/MDSC quantification. - Antigen-specific immune response assays. - Tumor growth inhibition, survival, and metastasis quantification. - Lymph node accumulation and biodistribution. - Kynurenine (KYN) level measurement for IDO inhibition. - Flow cytometry and immunohistochemistry for immune cell infiltration.

Key results: IL-2 micelles: Enhanced DC vaccine efficacy and increased antigen-specific CTL accumulation at tumor sites. - PMet-P(cdmPEG2K) micelles: Co-delivery of DOX and pIL-12 was more effective at inhibiting tumor growth than either agent alone. - M-CSF/CaCO₃-crosslinked micelles: Significantly inhibited tumor growth by enhancing T cell-mediated anti-tumor immune responses. - PEOz-PLA/Pluronic F127 mixed micelles: Co-loaded OVA and CL264; promoted DC uptake, cytokine production, cross-presentation, and prevented E.G7-OVA tumor growth. - PEG-PE/PSA hybrid micelles: Co-delivered Trp2 and CpG ODN; expanded antigen-specific CTLs and offered strong anti-tumor effects in a lung metastatic melanoma model. - PSSN10 micelles: DOX/PSSN10 micelles were more effective than DOXIL or free DOX in inhibiting tumor growth and prolonging survival in 4T1.2 tumor-bearing mice. - PEG2k-Fmoc-1-MT micelles: Enhanced IDO inhibition, decreased KYN, increased CD4⁺/CD8⁺ T cell proliferation, and improved tumor growth inhibition in a 4T1 breast cancer model. - CTLA-4 siRNA/PEG-PLA nanoparticles: Direct and effective T cell activation by targeting immune checkpoint pathways. - Anti-PD-1/PTX dual-sensitive micelles: Synergistic antitumor immunochemotherapy via PTX-induced ICD and PD-1/PD-L1 blockade. - POx-R848 micelles: Superior tumor-inhibiting effect in metastatic NSCLC relative to anti-PD-1 therapy or platinum-based chemotherapy; mobilized antitumor CD8⁺ immune responses. - CAR-encoding micelles (mPEG-bPEI-PEBP): Transfected Jurkat cells and induced CAR-Jurkat cells that secreted IFN-γ and IL-2 and showed cytotoxic effects against CD19-K562 cells.

Interpretation: Polymeric micelles can improve the therapeutic efficacy and reduce adverse effects of cancer immunotherapies by delivering antigens, antibodies, cytokines, adjuvants, and checkpoint inhibitors. Their chemical flexibility allows tuning of core/shell structure for controlled release, stimuli-responsiveness, and targeting. Although few polymeric micelle systems have advanced to clinical trials for immunotherapy, the field is expanding rapidly and polymeric micelles appear promising for translation into clinical cancer immunotherapy.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Most discussed systems are preclinical; clinical translation is limited. - Only a small proportion of patients respond to current immunotherapies (10–30%); solid tumors remain difficult to treat. - The TME is complex and not fully understood; tumor heterogeneity complicates vaccine design. - Long-term safety, CRS, neurotoxicity, and irAEs remain concerns, especially for CAR-T and checkpoint inhibitor therapies. - No large-animal validation or detailed clinical trial data are presented. - Manufacturing, scalability, and regulatory considerations are not deeply addressed.